Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Josh Ballard"'
Digital atomic scale fabrication an inverse Moore's Law – A path to atomically precise manufacturing
Autor:
John N. Randall, James H.G. Owen, Ehud Fuchs, Joseph Lake, James R. Von Ehr, Josh Ballard, Erik Henriksen
Publikováno v:
Micro and Nano Engineering, Vol 1, Iss , Pp 1-14 (2018)
There is an exciting opportunity to start a second digital revolution that will supersede the first digital revolution in information technology (IT) as the primary driver of scientific, technological, and economic growth. This new revolution will be
Externí odkaz:
https://doaj.org/article/9e1a33f565f54bfe82b4c1573e00e0b1
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Supplementary Data, Yeh, et al. from Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb220f9585897004967629e2407f636
https://doi.org/10.1158/1078-0432.22441213.v1
https://doi.org/10.1158/1078-0432.22441213.v1
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406a4a31b0cf89e0543cd3f66dfd4a9e
https://doi.org/10.1158/1078-0432.c.6518341.v1
https://doi.org/10.1158/1078-0432.c.6518341.v1
Autor:
Peter Olson, David Briere, Matthew A. Marx, Andrew Calinisan, Michael R. Burkhard, Niranjan Sudhakar, Jill Hallin, Lauren Hargis, Fell Jay Bradford, Guy Vigers, Ruth Aranda, Lars D. Engstrom, John P. Fischer, James G. Christensen, James F. Blake, Brian R. Baer, Josh Ballard, Vickie Bowcut
Publikováno v:
Molecular Cancer Therapeutics. 18:C069-C069
The ability to effectively target mutated KRAS has remained elusive despite decades of research. MRTX849 was identified via structure-based drug design as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properti
Autor:
Barb Brandhuber, Stephen S. Gonzales, Guy Vigers, Kevin Ronald Condroski, Jed Pheneger, Patrice Lee, Allen A. Thomas, Y. Le Huerou, J. De Meese, Robin Pedersen, Jie Lin, Todd Romoff, Greg Poch, Christine Lemieux, Gunawardana Indrani W, Boyd Steven A, May Han, Francis X. Sullivan, Darin Smith, Bryan Bernat, Tomas Kaplan, Walter E. DeWolf, Josh Ballard, S. Kirk Wright, Solly Weiler
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:2206-2210
Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mi
Autor:
Francis X. Sullivan, J. De Meese, Tomas Kaplan, Steven S. Gonzales, Josh Ballard, Solly Weiler, Joseph P. Lyssikatos, Thomas Daniel Aicher, Christine Lemieux, S. Kirk Wright, Barb Brandhuber, Gunawardana Indrani W, Allen A. Thomas, Todd Romoff, May Han, Kevin Ronald Condroski, Guy Vigers, Darin Smith, Bryan Bernat, Boyd Steven A, Y. Le Huerou, Walter E. DeWolf
Publikováno v:
Bioorganicmedicinal chemistry letters. 18(2)
Inhibition of the thiamine-utilizing enzyme transketolase (TK) has been linked with diminished tumor cell proliferation. Most thiamine antagonists have a permanent positive charge on the B-ring, and it has been suggested that this charge is required
Autor:
Darin Smith, Hurley Brian T, Kevin Koch, Lyssikatos Joseph P, Bryan Bernat, James D. Winkler, Barbara J. Brandhuber, Heidi Colwell, Eli M. Wallace, Patrice Lee, Tammie C. Yeh, Janet Parry, Stefan Gross, Vivienne Marsh, Ronald Evans, Josh Ballard, Allison L. Marlow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(5)
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these stud